MDM2

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Retrieved on: 
Tuesday, January 9, 2024

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
  • Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
  • KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
  • Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Retrieved on: 
Monday, October 16, 2023

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023, in Boston, Massachusetts and will also be shared at the 10th International MDM2 Workshop taking place October 15-18, 2023, in Tokyo, Japan.

Key Points: 
  • p53 remains intact (wild type) in approximately 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • In preclinical studies, MDM2 degraders have demonstrated the ability to overcome the MDM2 feedback loop observed with MDM2 SMIs and rapidly induce cell death in sensitive p53 wild-type cancer cell lines, even with brief compound exposure.
  • This may enable an improved therapeutic index, which could result in a superior efficacy and safety profile over MDM2 SMIs.
  • These data demonstrate in vitro efficacy of an MDM2 degrader, KTX-049, against p53 wild-type MCC cell lines that was achieved with brief compound exposure.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Tuesday, August 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Tuesday, August 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Retrieved on: 
Thursday, June 22, 2023

KT-253 is a highly potent and selective degrader that targets MDM2, the crucial regulator of the most common tumor suppressor, p53.

Key Points: 
  • KT-253 is a highly potent and selective degrader that targets MDM2, the crucial regulator of the most common tumor suppressor, p53.
  • p53 remains intact (wild type) in close to 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • “This orphan drug designation reinforces the potential of KT-253 to advance the treatment of AML by targeting MDM2, a protein that has been challenging to effectively drug with conventional medicines,” said Nello Mainolfi, Founder, President and CEO, Kymera Therapeutics.
  • Orphan drug designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

Retrieved on: 
Friday, June 9, 2023

The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.

Key Points: 
  • The data will be presented at the European Hematology Association (EHA) Congress, taking place from June 8-15, 2023, in Frankfurt, Germany.
  • KT-253 targets MDM2, the crucial regulator of the most common tumor suppressor, p53.
  • p53 remains intact (wild type) in close to 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • Patients in the KT-253 Phase 1 dose escalation study will receive IV doses of KT-253 administered once every 3 weeks.

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

Retrieved on: 
Friday, May 19, 2023

WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253. The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity of ascending doses of KT-253 in adult patients with relapsed or refractory high grade myeloid malignancies, acute lymphocytic leukemia (ALL), lymphomas, and solid tumors.

Key Points: 
  • WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.
  • KT-253 targets MDM2, the crucial regulator of the most common tumor suppressor, p53.
  • p53 remains intact (wild type) in close to 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • The study is intended to identify the recommended Phase 2 dose for KT-253, and will be comprised of two arms, with ascending doses of KT-253 in each arm.

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

Retrieved on: 
Monday, March 27, 2023

as chief medical officer of Terns oncology, effective May 1, 2023.

Key Points: 
  • as chief medical officer of Terns oncology, effective May 1, 2023.
  • Dr. Kuriakose brings more than a decade of clinical development and medical affairs experience spanning early through late phase development in several oncology indications at Novartis and Calithera Biosciences, where he most recently was serving as chief medical officer.
  • After Dr. Kuriakose commences his employment at Terns, Kerry Russell, M.D., will assume the role of chief medical officer of Terns metabolic with responsibility for Terns’ NASH and obesity programs.
  • I look forward to leveraging my experience to advance TERN-701 for the treatment of CML and expand Terns’ oncology franchise,” commented Dr. Kuriakose.

Kartos Therapeutics Appoints Dr. Srdan Verstovsek as Chief Medical Officer

Retrieved on: 
Thursday, March 2, 2023

Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer, today announced that Dr. Srdan (Serge) Verstovsek, MD, PhD, has been named Chief Medical Officer (CMO).

Key Points: 
  • Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer, today announced that Dr. Srdan (Serge) Verstovsek, MD, PhD, has been named Chief Medical Officer (CMO).
  • Dr. Verstovsek is a world-renowned physician-scientist and a leading global authority on the treatment of myeloproliferative neoplasms (MPN), including myelofibrosis (MF).
  • Dr. Verstovsek has collaborated extensively with Kartos in recent years and has been actively involved in all the company’s MPN clinical studies.
  • “We are humbled that Dr. Serge Verstovsek has decided to continue his extraordinary career as part of the Kartos team,” said Jesse McGreivy, MD, Chief Executive Officer of Kartos Therapeutics.